drugset / Trial / NCT00802737

Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL)

NCT00802737

Phase 4 Completed 29 enrolled GlaxoSmithKline Genmab · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the trial is to investigate the efficacy and safety of ofatumumab retreatment and maintenance in patients with chronic lymphocytic leukemia who have previously responded or had disease stabilization after ofatumumab in an ongoing trial (Hx-CD20-406).

Timeline

Start
2009-01
Primary completion
2011-09
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Ofatumumab Monoclonal antibody 2000 mg